Career

Jan 17, 2025, 21:06

Matthew E. Ros Was Appointed Chief Operating Officer at Verastem Oncology

Verastem Oncology recently named Matthew E. Ros as it’s Chief Operating Officer.

Matthew Ros is an executive with over 25 years of leadership experience in the biopharmaceutical and oncology sectors.

He currently serves as the Chief Operating Officer at Verastem Oncology, where he drives the company’s strategic and operational initiatives.

Matthew’s expertise spans corporate strategy, clinical development, business development, finance, and operational management.

Previously, Matthew was the CEO and Board Member of Fore Biotherapeutics, an early-stage oncology company focused on advancing a novel BRAF inhibitor. During his tenure, he successfully stabilized the company, reframed its strategic focus, and advanced the clinical development of plixorafenib.

His efforts led to the FDA’s endorsement of the Phase 2 dose, along with the approval of a new IND and Fast Track and Orphan Drug designations.

Additionally, he raised $75 million in Series D financing, securing the company’s financial position and furthering its development.

Before Fore Biotherapeutics, Matthew held significant roles at Epizyme, Inc., where he served as Executive Vice President, Chief Strategy and Business Officer.

In this role, he was instrumental in advancing the company from mid-stage to registrational development, securing two FDA approvals, and building a commercial infrastructure for TAZVERIK®, a first-in-class oncology treatment.

He also played a key role in raising over $400 million through public equity financing and executing strategic collaborations, including with HUTCHMED and Quest Diagnostics.

Matthew’s career also includes a successful tenure at Sanofi Genzyme, where he was the Vice President and COO, overseeing a $1.4 billion oncology franchise.

He led the restructuring of the oncology division, driving growth and improving operational efficiencies. Under his leadership, the franchise achieved 9% core brand growth across a diverse portfolio of solid tumor and hematology products.

Matthew holds a Bachelor of Science in Business Administration from the State University of New York at Plattsburgh. His broad experience in oncology, combined with his leadership skills, has enabled him to guide organizations through complex clinical and commercial challenges, ultimately bringing new and innovative therapies to market.